Full-Time
Posted on 6/11/2025
Develops and commercializes prescription medicines
No salary listed
Mid
Mumbai, Maharashtra, India
AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatments; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by providing effective treatments for serious diseases while collaborating with the scientific community to improve their research capabilities.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
AstraZeneca enters into collaboration with CSPC
Fixed-duration Calquence approved in EU for 1L CLL
Sortera Bio, a Cambridge biotech, secured a £7.5m pre-seed round led by Cambridge Innovation Capital, with AstraZeneca and BioNTech participating. The funding will enhance Sortera's Deep Screening platform, which uses AI for drug discovery. Co-founded by Dr. Ben Porebski and Dr. Philipp Holliger, Sortera aims to deliver precision biologics. The technology was developed at the MRC Laboratory of Molecular Biology with AstraZeneca's support.
AstraZeneca has shared P-III (MATTERHORN) trial data assessing perioperative Imfinzi + FLOT (n=474) vs PBO + FLOT (n=474) in 948 pts with stage II-IVA G/GEJ cancers at ASCO 2025
2 June 2025 BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris. (Note: Italicised terms have the same meaning as given in the Listing Rules.) Date: 2 June 2025 Name of applicant: ASTRAZENECA PLC Name of scheme: ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS -RELATED SHARE OPTION PLAN;